parallel randomized trial

S002974

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Other conditionsS002974

Design

Randomized: 20
Start year
Treatment: , follow-up 1 weeks
Countries: China (1 sites)
Sponsor: Sanofi (industry)
Eligibility: healthy Chinese adults aged 18 to 45; BMI 19.0 to 27.9

Conduct and analysis

Blinding: open label
Sequence generation: not reported
Allocation concealment: not reported
Outcome adjudication: not reported
Primary estimand: not stated
Analysis population
Missing data

Arms

Arm	Treatment	Background	Randomized	Analyzed	Completed treatment
A1	insulin glargine and lixisenatide (iGlarLixi) iGlarLixi 10 U/10 ug	lifestyle: not reported	10
A2	insulin glargine and lixisenatide (iGlarLixi) iGlarLixi 30 U/15 ug	lifestyle: not reported	10

Baseline characteristics

As printed in the trial reports or registry, per arm or for the whole trial.

Characteristic	Statistic	Whole trial ALL
age	mean (years)	29.1
bmi	mean (kg/m2)	23.6
other male	percent	60
weight	mean (kg)	66.0

Results

2 adjudicated result lines, grouped by outcome. Open an outcome to see its values.

Serious adverse events (2 lines; O25)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
	A1	events				0 / 10	not stated; randomized; R0006803:Results
	A2	events				0 / 10	not stated; randomized; R0006803:Results